Differences seen in IL-1α and IL-1β signaling in murine AAA models suggest that targeting of these molecules could produce different effects and that targeting their common receptor, IL-1R1, might be the preferred target for pharmacologic inhibition studies [48]. This evidence concerns the gene IL1A and triple-A syndrome.